Objective: Transforming growth factor-b (TGFb) is a major regulator of cartilage homeostasis and its deregulation has been associated with osteoarthritis (OA). Deregulation of the TGFb pathway in mesenchymal stem cells (MSCs) has been proposed to be at the onset of OA. Using a secretome analysis, we identified a member of the TGFb family, TGFb-induced protein (TGFbi or bIGH3), expressed in MSCs and we investigated its function and regulation during OA. Design: Cartilage, bone, synovium, infrapatellar fat pad and bone marrow-MSCs were isolated from patients with OA or healthy subjects. Chondrogenesis of BM-MSCs was induced by TGFb3 in micropellet culture. Expression of TGFbi was quantified by RT-qPCR, ELISA or immunohistochemistry. Role of TGFbi was investigated in gain and loss of function experiments in BM-MSCs and chondrocytes. Results: TGFbi was up-regulated in early stages of chondrogenesis and its knock-down in BM-MSCs resulted in the down-regulation of mature and hypertrophic chondrocyte markers. It likely occurred through the modulation of adhesion molecules including integrin (ITG)b1, ITGb5 and N-cadherin. We also showed that TGFbi was upregulated in vitro in a model of OA chondrocytes, and its silencing enhanced the hypertrophic marker type X collagen. In addition, TGFbi was up-regulated in bone and cartilage from OA patients while its expression was reduced in BM-MSCs. Similar findings were observed in a murine model of OA. Conclusions: Our results revealed a dual role of TGFbi during chondrogenesis and pointed its deregulation in OA joint tissues. Modulating TGFbi in BM-MSCs might be of interest in cartilage regenerative medicine.
Introduction
Osteoarthritis (OA) is the most common rheumatic disease affecting all joint tissues including cartilage, sub-chondral bone, synovium and fat pad 1 . It results in progressive destruction of articular cartilage and loss of joint function leading to morbidity and disability in adults. This induces a societal burden that will increase in the coming years due to the aging of population and increased prevalence of obesity and metabolic disorders 2 . Although the aetiology of OA is still imperfectly understood, a number of environmental and genetic factors contribute to the breakdown of cartilage homeostasis and OA initiation. Evidence from genomewide association studies has emerged that growth factors belonging to the transforming growth factor-b (TGFb) family play a role in the development of OA 3 .
Members of the TGFb superfamily can be divided into the TGFb and activin group, the bone morphogenetic protein (BMP) group and the growth and differentiation factor (GDF) group 4 . The TGFb signalling is essential for articular cartilage homeostasis. It is rapidly upregulated by mechanical loading, stimulates proteoglycan synthesis and blocks the expression of chondrocyte hypertrophic genes 5 . Indeed, under physiological conditions, TGFb is expressed at basal levels in articular cartilage or upregulated by loading and prevents chondrocyte terminal differentiation and cartilage degeneration 6 . However, TGFb signalling is deregulated in OA and high concentrations of TGFb can be found in the synovial fluids of patients. Soluble TGFb is produced by activated synovial cells and released from reservoirs in the cartilage matrix upon its degradation. High levels of TGFb result in preferential activation of the SMAD1-5-8 pathways instead of the SMAD2-3 pathways and in upregulation of genes involved in fibrogenesis and hypertrophy leading to synovial fibrosis and osteophyte formation 7 .
In OA, osteophytes arise from chondrocyte terminal differentiation of mesenchymal progenitors residing in the periosteum due to the increased expression of TGFb. TGFb expression is also increased in the subchondral bone where are located mesenchymal stem/stromal cells (MSCs) . Demonstration that deregulation of TGFb signalling in MSCs is involved in OA progression or initiation came from the study of Zhen and co-authors 8 . They showed that knock-down of TGFb type II receptor in nestin-positive MSCs resulted in less severe cartilage lesions in mice whereas transgenic expression of TGFb1 in osteoblasts induced OA. Indeed, excessive subchondral bone formation in OA is associated with enhanced TGFb activity in osteoblasts and MSCs. Other studies have reported cartilage resident MSC-like progenitors with senescence features, which might be related to failure of repair 9 and the possible involvement of synovium-derived MSCs in cartilage repair following joint injury 10 . Our hypothesis was that dysregulation of TGFb signalling in MSCs is responsible for lack of cartilage repair in OA. Based on a previous secretome analysis of MSCs derived from bone marrow and adipose tissue, we identified basal secretion of several TGFb family members, including TGFb-induced gene product-h3 (TGFbi/BIGH3/RGD-CAP) 11 . The aim of the present study was to determine the functional role of TGFbi in MSCs and to investigate its deregulation in OA.
Method

Cell culture
Human tissue specimens were recovered from post-mortem or amputated healthy subjects and patients with grade IV OA, aged 52.5 ± 8.5 years and 74.4 ± 5.1 years, respectively. The study was approved for OA specimen recovery by the French Ministry of Research and Innovation and the Personal data Protection ethics Committee (CPP) of Languedoc-Roussillon (approval DC-2010-1185) and CPP of Paris V, Ile de France and the Consultative Committee on the Treatment of Information in Research in Health field (CCTIRS) (approval 15-623-ter). Healthy tissues were recovered after approval by the Agence de la Biom edecine (authorization #: PFS16-006) for post-mortem subjects or for amputated patients (C17-53). Cartilage, bone, synovium and infrapatellar fat pad samples were recovered from the same patients, cut in small pieces and weighted. Supernatants were produced using 1 g tissue/6 mL IMDM medium containing 1% penicillin/streptomycin and 1% glutamine incubated at 37 C for 24 h. For RNA extraction, 300 mg of each tissue were snap frozen and stored at À80 C. MSCs isolated from bone marrow (BM-MSCs) or adipose tissue (ASCs) were characterized by phenotyping and trilineage differentiation potential as described 12 . They were cultured in aMEM containing 2 mmol/mL glutamine, 100 mg/mL penicillin/streptomycin, 10% foetal calf serum (FCS) and 1 ng/mL basic fibroblast growth factor (bFGF) (R&D Systems, Lille). Human chondrocytes were isolated from knee cartilage and cultured in DMEM supplemented with 2 mmol/mL glutamine, 100 mg/mL penicillin/streptomycin, 10% FCS, 5 mg/mL insulin, 5 ng/mL bFGF till passage 1 13 .
Collagenase-induced osteoarthritis mouse model
The study was conducted in accordance with guidelines and regulations of the Ethical Committee for animal experimentation of the Languedoc-Roussillon (Approval 5349-2016050918198875). The experiment was performed after final approval given by the French Ministry for Education, Higher Education and Research. Collagenase-induced osteoarthritis (CIOA) model was performed as previously described 14 . They were euthanatized at day 7, 14, 42. Hind paws were collected and fixed in formaldehyde 3.7% for 2 days before histological processing.
MSC differentiation and chondrocyte culture
BM-MSCs were differentiated towards chondrocytes by culture in micropellet for 21 days. Briefly, 2.5 Â 10 5 BM-MSCs were centrifuged in 15 mL conical tubes and cultured in DMEM high glucose (Lonza, Levallois) with 100 mg/mL penicillin/streptomycin, 0.35 mM proline, 0.1 mM dexamethasone, 0.17 mM ascorbic acid-2phosphate, 1 mM pyruvate sodium, 1% insulin-transferrin-selenic acid (Lonza) and 10 ng/mL TGF-b3 or 100 ng/mL BMP-2 or IGF-1 (R&D Systems). BM-MSCs were differentiated towards osteoblasts or adipocytes by culture in inductive conditions for 21 days as described 15 .
For the model of late passages, chondrocytes were maintained till reaching sub-confluency and replated at 6000 cells/cm 2 till passage 3. Otherwise, chondrocytes were used at Passage 1. After seeding, chondrocytes were cultured for 72 h before stimulation with 10 ng/mL IL-1b for 72 h or 10 ng/mL TGFb3 for 24 h (R&D Systems). Media were replaced for 24 h before recovering supernatants and cells.
Cell transfection
BM-MSCs and chondrocytes were transfected at 60% confluence with 50 nM of control siRNA (siCTRL) or TGFbi siRNA (siTGFbi) (Ambion, ThermoFisher Scientific, Illkirsch) using Oligofectamine reagent (Life Technologies, Courtaboeuf). BM-MSCs transfection was done twice: at day 3 and 1 before pellet formation. Chondrocytes were harvested 1 week after transfection for RNA extraction.
Protein analysis
TGFbi was quantified in culture supernatants by ELISA (Clin-iSciences, Nanterre). Phospho-SMAD3 and 1 were quantified in cell extracts by InstantOne ELISA assays as indicated by supplier (eBioscience, Paris). For Western blotting, cells were incubated with RIPA (Sigma Aldrich, Saint-Quentin Fallavier) containing Halt protease inhibitor cocktail (150 mL/3 pellets) at 4 C for 30min. Cell lysates were incubated in Bolt LDS sample buffer and Bolt sample reducing agent at 70 C for 10min (ThermoFisher Scientific). Protein extracts (50 mg) were analyzed by SDS-PAGE on Bolt 4e12% Bis-Tris Plus resolving gels, followed by transfer to nitrocellulose membranes. Membranes were blocked in Tris Buffered Saline containing 5% milk for 2 h and incubated with anti-TGFbi (1:200, Proteintech, Manchester) and anti-bactin (1:5,000, Sigma) antibodies at 4 C overnight. Membranes were then incubated with Horseradish peroxidase-labeled anti-mouse IgG antibody (1:100,000, Sigma) for 2 h. Bands were scanned using ChemiDoc XRS þ Imager (Bio Rad, Les Ulis).
Immunohistological analysis
Tissue samples from mice were fixed in 3.7% formaldehyde for 2 days and decalcified using 10% EDTA for 21 days before being processed. Pellets were fixed in 3.7% formaldehyde at room temperature for 1 h. Antigen retrieval was done on pellets with 1 mg/ mL hyaluronidase (Sigma Aldrich) at 37 C for 1 h or on tissue sections with citrate buffer (10 mM citric acid, 0.05% Tween 20, pH 6.0) at 70 C overnight followed by 1 mg/mL hyaluronidase at 37 C for 15min and 0.1 U/mL chondroitinase ABC (Sigma Aldrich) at 37 C for 1 h. Immunolabelling was performed using anti-type II collagen (1:50, Acris, Interchim), anti-aggrecan (1:1000, Merck, Molsheim), anti-TGFbi (1:100, Proteintech) primary antibodies at 4 C overnight and UltraVision Detection System Anti-Polyvalent kit (Lab Vision, Interchim, Montluçon).
RNA extraction and RT-qPCR
RNA was extracted from pellets or cells using the RNeasy kit and from infrapatellar fat pad or synovium using the RNeasy Lipid Tissue Kit (Qiagen, Courtaboeuf). For cartilage and bone, RNA was isolated with 0.1 g/mL TRIzol reagent (ThermoFisher Scientific) followed by chloroform and phenol acid extraction. RNA (0.5 mg) was reverse transcribed using 100 units of the M-MLV reverse transcriptase (ThermoFisher Scientific, Illkirch) and PCR reactions were performed as described 16 . All details for primer sequences (SYBR Green technologies) are described in Table 1 . All values were normalized to RPS9 housekeeping gene and expressed as relative expression or fold change using the respective formulae 2 ÀDCT or 2 ÀDDCt .
Statistical analyses
Statistical analysis was performed with GraphPad Prism Software. Each sample/cell was independent and represented an experimental unit providing a single outcome. Normal distribution and variance homogeneity of values were determined with ShapiroeWilk and Fisher (2 groups) or Bartlett (>2 groups) tests, respectively, followed by appropriate tests. Description of the tests used are detailed in each figure. Data are presented as the mean ± SD. *: P value < 0.05.
Results
TGFbi is expressed in MSCs from healthy individuals and downregulated in MSCs from OA patients From a previous proteomic study investigating the secretome of BM-MSCs and ASCs 11 , we discovered that among members of the TGFb family, latent binding protein (LTBP)1, LTBP2 and TGFbi were mutually expressed [ Fig. 1(A) ]. We selected TGFbi because its functional role in MSCs and cartilage homeostasis or physiopathology is still unclear. TGFbi expression was confirmed in BM-MSCs and ASCs at the mRNA and protein levels but at significantly higher levels in BM-MSCs [ Fig. 1 (B)e(C)]. In addition, TGFbi was expressed at significantly lower levels in cells belonging to other embryonic origin, such as endoderm-derived primary hepatocytes. Of interest, mRNA and protein expression of TGFbi was dramatically down-regulated in BM-MSCs from late stage OA patients, as compared to healthy subjects [ Fig. 1 
Expression of TGFbi is up-regulated in cartilage and bone from OA patients
Demonstration that TGFbi is down-regulated in OA BM-MSCs questioned on its expression in other joint tissues from OA patients. We therefore compared TGFbi expression in cartilage, bone, synovium and infrapatellar fat pad from healthy subjects and patients at latest stage of OA, who were undergoing surgery. Expression levels of TGFbi mRNA were significantly up-regulated in cartilage and bone from OA patients but unchanged in synovium or infrapatellar fat pad By contrast, intense staining for TGFbi was observed in the upper layers of cartilage from OA patients, in areas with signs of chondrocyte proliferation, of high erosion or in osteophytes (not shown). Similarly, in the CIOA mouse model, strong staining for TGFbi was visualized in the articular cartilage and particularly, in osteophytes (Supl. figure, panel (A) ). In this model, we also revealed up-regulation of TGFbi mRNA at all time times during the course of the disease (Supl. figure, panel (B) ). Similar findings were obtained in the aging and destabilization of the median meniscus (DMM) models (data not shown). Altogether, these data supported a dysregulation of TGFbi in OA.
TGFbi is up-regulated in IL1b-treated chondrocytes
Expression of TGFbi being dysregulated in OA samples, we wanted to determine its expression kinetics in an in vitro model of OA-like chondrocytes. We first used the model of freshly isolated chondrocytes induced to dedifferentiate by serial passages, in which expression of chondrocyte anabolic markers is lost, reproducing characteristics of OA cartilage 17 . As expected, we observed a down-regulation of type II collagen and aggrecan while type I collagen was up-regulated as soon as passage 1 [ Fig. 3(A) ]. However, concomitantly with decreased expression of anabolic markers, expression of TGFbi was down-regulated in dedifferentiated chondrocytes [ Fig. 3(B) ]. We therefore investigated the modulation of TGFbi expression in another in vitro model of OA: freshly isolated chondrocytes cultured with IL-1b. In this model, IL- TGGGTGGCATCGTAGGTCTG  AGG  TCGAGGACAGCGAGGCC  TCGAGGGTGTAGCGTGTAGAGA  AP  CCACGTCTTCACATTTGGTG  GCAGTGAAGGGCTTCTTGTC  COLIIB  CAGACGCTGGTGCTGCT  TCCTGGTTGCCGGACAT  COLX  GTGGACCAGGAGTACCTTGC  TGCTGCCACAAATACCCTTT  ITGaV  AGGAGAAGGTGCCTACGAAGCT  GCACAGGAAAGTCTTGCTAAGGC  ITGb1  GGATTCTCCAGAAGGTGGTTTCG TGCCACCAAGTTTCCCATCTCC  ITGb3  CATGGATTCCAGCAATGTCCTCC  TTGAGGCAGGTGGCATTGAAGG  ITGb5  GCCTTTCTGTGAGTGCGACAAC  CCGATGTAACCTGCATGGCACT  MMP13  TAAGGAGCATGGCGACTTCT  GTCTGGCGTTTTTGGATGTT  N-CAD  CCTCCAGAGTTTACTGCCATGAC  GTAGGATCTCCGCCACTGATTC  OC  GGCGCTACCTGTATCAATGG  TCAGCCAACTCGTCACAGTC  RUNX2  CGGAATGCCTCTGCTGTTAT  TTCCCGAGGTCCATCTACTG  TGFb1  AAGAAGCGTGCTTTGGATGCGG  ATGCTCCAGCACAGAAGTTGGC  TGFb2  AAGAAGCGTGCTTTGGATGCGG  ATGCTCCAGCACAGAAGTTGGC  TGFb3 CTAAGCGGAATGAGCAGAGGATC . Finally, we investigated the effect of TGFbi silencing in chondrocytes. Both TGFbi mRNA and protein levels were downregulated by a two-fold factor using siRNA interference approach, although statistically only for mRNA levels [ Fig. 3I ]. This downregulation did not significantly modulate most of chondrocyte genes but significantly increased the expression of the hypertrophic chondrocyte marker, type X collagen [ Fig. 3(J) ].
Upregulation of TGFbi during the early stage of chondrogenic differentiation of BM-MSCs
With regards to the expression of type X collagen in late stage of chondrogenesis, we investigated the expression of TGFbi during the differentiation of BM-MSCs. Chondrogenic differentiation of BM-MSCs was induced by culture in micropellet in presence of TGFb3 for 21 days. TGFbi expression peaked at days 1e3 and returned to basal levels as soon as day 7, till day 21 [ Fig. 4(A) ]. Up-regulation of TGFbi was also noticed in control conditions (MSCs cultured in aggregates in absence of TGFb3) but the expression levels were not statistically different from day 0, except for day 3. Of interest, expression of TGFbi is low when the expression of the chondrocyte markers, Sox9, type IIB collagen, Aggrecan and type X collagen are high at day 21 (compared to day 0 or to micropellets cultured without TGFb3) [ Fig. 4(B) ]. Protein levels of TGFbi tended to be increased in pellet culture supernatants of TGFb3-induced pellets (2-fold factor at day 4 and 4.3-fold factor at day 21), as compared to un-induced pellets [ Fig. 4(C) ]. However, they were significantly lower at day 21 as compared to day 4. Lower amounts of TGFbi were observed in pellet supernatants than in MSC supernatants (day 0), which was likely due to retention of the protein in the pellet extracellular matrix. Immunohistochemical analysis detected TGFbi protein in TGFb3-induced pellets at day 7 (not shown) and at day 14 while at day 21, the staining appeared less intense [ Fig. 4(D) ]. By contrast, chondrocyte markers, aggrecan and type II collagen, as well as proteoglycan secretion were slightly detected at day 14 but clearly distinguished at day 21. Interestingly, a significant positive correlation was found between TGFbi mRNA level at day 0 and mRNA levels of the 3 main chondrocyte markers (Sox9, type IIB collagen, aggrecan) at day 21 [ Fig. 4(E) ]. We also noticed that TGFbi was up-regulated by TGFb3 from day 1 to day 3 of pellet culture but not by IGF1 or by another member of the TGFb family (BMP2) [ Fig. 4(F) ]. Finally, TGFbi was not a marker of commitment of BM-MSCs to progenitor cells but was specific for chondrogenesis since a significant down-regulation of TGFbi was observed during Fig. 4(G) ]. In addition, TGFbi expression remained stable or tended to decreased during adipogenesis [ Fig. 4(H) ]. Indeed, we demonstrated that TGFbi expression was specifically increased at early stages of chondrogenesis but was decreased upon chondrocyte maturation, indicating that the overall process was associated with a tight regulation of TGFbi.
Critical role of TGFbi in the chondrogenic differentiation of BM-MSCs
To determine whether TGFbi has a cell-autonomous function in chondrogenesis, we used a loss-of-function approach. TGFbi silencing resulted in a reduction of mRNA expression by 89% and 74% at day 0 and day 21, respectively [ Fig. 5(A) ]. TGFbi protein was reduced by 98% at day 4% and 66% at day 21 [ Fig. 5(B) ]. The TGFbi protein was undetectable by western blotting at day 4 after siRNAmediated silencing [ Fig. 5(C) ]. Down-regulation of TGFbi reduced the expression of mature and hypertrophic chondrocyte markers, type IIB collagen, aggrecan, MMP13, type X collagen and alkaline phosphatase by day 21 [Fig. 5(D) ]. The reduction was however not significant for type IIB collagen and alkaline phosphatase. To determine if the down-regulation of TGFbi alters TGFb signalling, we quantified the expression of TGFb isoforms or phosphorylated Smad proteins and found no significant change as compared to control MSCs [ Fig. 5(EeF) ]. However, at early stages, we noticed that siTGFbi-transfected pellets were flat and less dense than control pellets (not shown). We therefore investigated the effect of TGFbi silencing on adhesion molecules known to interact with TGFbi and/or to be important during initial stages of chondrogenesis. Of interest, down-regulation of TGFbi led to a low but significant increase of integrin (ITG)b1 at day 0 and a decrease of ITGb5 and N-cadherin (N-CAD) at day 3 [ Fig. 5(G) ]. Finally, the down-regulation of TGFbi increased MSC differentiation towards osteoblasts as shown by increased mineralization and expression of osteoblast markers [ Fig. 5(H) ]. Altogether, these data indicated a key role of TGFbi at the early stage of chondrogenesis, possibly through the modulation of important adhesion molecules and, at the late stage of chondrocyte hypertrophy, when mineralization occurs. TGFbi may act as an anti-mineralizing factor whose expression is decreased during both osteoblastogenesis and chondrogenesis allowing mineralization to occur.
Discussion
Here, we show that TGFbi regulated the chondrogenic differentiation of adult BM-MSCs. TGFbi revealed a dual role stimulating the early phase of proliferation and differentiation while inhibiting the late phase of hypertrophy and mineralisation. For the first time, we further evidenced that TGFbi was upregulated in articular cartilage and bone of patients with OA suggesting a deregulated function in the disease.
Our study shows that TGFbi was up-regulated in early stages of chondrogenic differentiation of adult BM-MSCs and downregulated in terminal stages. TGFbi upregulation in early stages is likely occurring upon TGFb and Smad signaling pathway activation as proposed elsewhere 18 . In mouse, previous studies on embryonic and post-natal limb development reported that TGFbi was abundantly expressed in mesenchymal condensation areas, perichondrium, periosteum, prehypertrophic chondrocytes but absent in hypertrophic chondrocytes 19, 20 . Increased expression of TGFbi was also observed at early stages of differentiation of the prechondrogenic cell line ATDC5 while it was decreased at late stages 19 . Other studies in chick embryos have shown that TGFbi was expressed in the prehypertrophic zone of vertebral cartilage but not in the proliferative zone. Moreover, addition of TGFbi on growth plate chondrocytes resulted in decreased mineralization 21 . These studies suggested an inhibitory role of TGFbi on mineralization and late chondrogenic differentiation. This is also supported by our data showing its downregulation during the osteoblastogenic differentiation of BM-MSCs. TGFbi was previously shown to inhibit the differentiation of the pre-osteoblastic cell line KS-483 and to be down-regulated in BM-MSCs induced to differentiate into osteoblasts 22, 23 . In mature osteoblasts, TGFbi inhibited late differentiation and mineralization 24 . Here we confirmed these data using a RNA interference strategy. Our data and those from the literature indeed support a biphasic function of TGFbi during the chondrogenic differentiation of adult BM-MSCs. During the early stage of chondrogenesis, TGFbi likely regulates the condensation of BM-MSCs, a process involving cell proliferation and cell-to-cell contact, by bridging interactions between cells, collagens and proteoglycans. Our results revealed that TGFbi modulated expression of the adhesion molecules ITGb1, ITGb5, N-CAD, which are required at early stages of MSC condensation and chondrogenesis. It may also stimulate the proliferation of BM-MSCs and pre-chondrocytes at this early stage 21 . TGFbi expression is then down-regulated at the terminal stage of chondrogenesis, suggesting an inhibitory role on hypertrophy and mineralization. TGFbi contains gammacarboxylated glutamic acid residues that are known to bind calcium with high affinity thereby inhibiting mineralization. However, whether TGFbi is subject to extensive gamma-carboxylation is still under debate 25 . In our study, silencing of TGFbi in BM-MSCs before inducing differentiation resulted in the down-regulation of both mature and hypertrophic chondrocyte markers. This evoked an impact primarily on the early condensation phase by reducing and/ or delaying the overall differentiation process together with the inhibition of late differentiation.
Role of TGFbi has not been described in OA. Some transcriptomic studies have listed the upregulation of TGFbi at 2 weeks after OA induction in the DMM model or in damaged zones of cartilage from OA patients 26e28 . Proteomic studies have reported the upregulation of TGFbi in the cartilage from OA patients 29, 30 . However to our knowledge, a single study validated an increased expression of TGFbi transcripts in damaged vs non damaged regions from OA joints 27 . Nevertheless, cartilage matrix degradation was reported in TGFbi knock-out mice that was associated with reduced type II collagen levels and higher MMP13 expression in cartilage 31 . Although other features of OA were not investigated, these data suggested that TGFbi deficiency was associated with the degradation of cartilage matrix similar to what occurs in OA. Here, we demonstrate for the first time the up-regulation of TGFbi at the mRNA and protein levels in cartilage and bone from OA patients as compared to healthy subjects. We observed a preferential locali- with clusters of chondrocytes, both in OA patients and in mice with OA. This likely indicates that TGFbi upregulation may be involved in the modulation of signalling pathways that are essential for the integrity and repair of cartilage. By reference to the role of TGFbi during chondrogenesis, it may reflect an attempt of chondroprogenitor cells to differentiate and secrete extracellular matrix components to induce cartilage regeneration or repair. This might occur at the early stages of the disease as shown in the DMM model where TGFbi expression was only detected till week 2 after disease induction 26 but could be not the case in samples at the latest stages as used here. This may also reveal an attempt to inhibit mineralisation that occurs in cartilage and sub-chondral bone as a result of TGFb pathway activation at late stages of OA 32 . Of interest in the model of chondrocyte dedifferentiation, the expression of both TGFbi and other chondrocyte markers decreased while TGFbi silencing did not affect the expression of chondrocyte markers. Only type X collagen was increased after siTGFbi transfection. Expression of type X collagen was previously shown to precede alkaline phosphatase expression and mineralization in chondrocytes 33 . In the pellet model of BM-MSCs differentiated into chondrocytes, alkaline phosphatase secretion was detected at day 21 and type X collagen expression at day 14 but no mineralization was observed 34 . Indeed, our data indicated that TGFbi regulates type X collagen expression and hypertrophic chondrocyte phenotype, which could precede cartilage calcification. Alternatively, TGFbi up-regulation may reflect the deregulation of the TGFb pathway in OA 3, 7, 35 . TGFbi up-regulation was seen both in IL1binduced OA chondrocytes in vitro and in cartilage samples from OA patients. Interestingly, TGFbi was down-regulated in infrapatellar fat pad and BM-MSCs recovered from OA patients. This may indicate a lower capacity of BM-MSCs from OA patients to undergo a differentiation program and/or to counteract the inflammatory and pathological environment in OA. MSC-like chondroprogenitor cells with the capacity to migrate into and populate diseased cartilage tissue ex vivo has been reported 36 . Presence of native MSCs in the joint cavity and spontaneous MSC-mediated repair of cartilage has also been described in vivo (for review, see 10 ). Evidence that multiple niches of MSCs exist in the joint cavity has put forward the possibility that MSCs with proliferative and unipotent differentiation potential may efficaciously repair microdefects in injured cartilage. Studies on exogenous MSC injection in the joint space have also reported neo-meniscus formation and integration into synovium confirming differentiation of MSCs into joint tissues 37 . Less is known about a deregulated function of MSCs in OA in situ but knocking-out the TGFb pathway in nestin-positive MSCs in vivo was shown sufficient to attenuate OA 8 . Whether the downregulation of TGFbi may be predictive of BM-MSCs efficiency to repair cartilage lesions in vivo warrants further investigation.
Altogether, our study identified TGFbi as a novel factor involved in the chondrogenic differentiation of BM-MSCs. Its expression is deregulated in OA joint tissues, suggesting a role in the formation of hypertrophic cartilage and mineralization. Modulating TGFbi expression in BM-MSCs might be of interest to enhance their therapeutic effect in cartilage regenerative medicine.
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